Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Next Previous
Search
Trial Profile

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ritlecitinib (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEGRO-2b/3
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Mar 2025 Results assessing benefit-risk profile of two doses of ritlecitinib 50mg and 30 mg evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib, published in the Journal of Dermatology
    • 01 Nov 2023 Results of subgroup analysis (n=105 adolescents ) evaluating the efficacy and safety of ritlecitinib, published in the Pediatric Dermatology
    • 19 Sep 2023 According to a Pfizer media release, the European Commission (EC) has granted marketing authorization for LITFULO (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top